Observational studyBMC infectious diseases2026
Validation of ICD-10-CM diagnosis codes for identifying COVID-19 cases using administrative claims data in Taiwan.
Observational study in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAccurate identification of COVID-19 cases is essential for real-world studies. This study assessed the validity of ICD-10-CM code U07.1 for identifying COVID-19 cases in administrative claims data in Taiwan.
methodsThis observational validation study linked National Health Insurance claims with laboratory-confirmed SARS-CoV-2 RT-PCR results from a multi-institutional database. We included 127,300 outpatient, emergency, and inpatient encounters from 2022. Positive and negative predictive values (PPV, NPV), sensitivity, and specificity were calculated using RT-PCR results as the reference standard, with stratified analyses conducted by clinical setting, time period, patient demographics, and hospital level.
resultsOverall, the U07.1 code demonstrated high PPV (95.3%) and specificity (99.5%), but moderate NPV (77.9%) and low sensitivity (26.6%). While PPVs remained consistently high across all clinical settings (> 91%), NPVs varied significantly, being lowest in outpatient visits (41.3%). Temporally, NPV and sensitivity were lowest during April-June 2022 (57.7% and 14.9%, respectively), coinciding with the peak outbreak and the transition toward antigen-based diagnostic policies. Sensitivity was markedly higher among inpatients (84.4%) and older adults aged ≥ 80 years (60.5%) compared to younger populations.
conclusionICD-10-CM U07.1 is a highly reliable marker for identifying confirmed COVID-19 cases in Taiwan's claims data. However, the low overall sensitivity and substantial variability in NPV suggest significant under-capture of mild infections, particularly in outpatient settings. Researchers should exercise caution when using this code to estimate total disease burden or when defining code-negative control cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.